The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma

Bibliography

• Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematol Am Soc Hematol Educ Program 2009;566-7
   PubMedGoogle Scholar
• Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013;41(1):230-7
   PubMed Web of Science ®Google Scholar
• Available from: www.fda.org
   Google Scholar
• Available from: www.ema.europa.eu
   Google Scholar
• Hanada M, Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 1992;45(11):1746-52
   PubMed Web of Science ®Google Scholar
• Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999;96(18):10403-8
   PubMed Web of Science ®Google Scholar
• Sin N, Kim KB, Elofsson M, et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999;9(15):2283-8
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67(13):6383-91
   PubMed Web of Science ®Google Scholar
• Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013;27(2):430-40
   PubMed Web of Science ®Google Scholar
• Steele JM. Carfilzomib: a new proteasome inhibitor for relapsed or refractory multiple myeloma. J Oncol Pharm Pract 2013; Epub ahead of print
   PubMedGoogle Scholar
• Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011;39(10):1873-82
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15(22):7085-91
   PubMed Web of Science ®Google Scholar
• Badros AZ, Vij R, Martin T, et al. Phase I Study of carfilzomib in patients (Pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiency. Blood (ASH Annual Meeting Abstracts) 2009;114:3877
   Google Scholar
• Badros AZ, Vij R, Martin T, et al. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. J Clin Oncol 2010;28(15 Suppl):abstract 8128
   Google Scholar
• Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012;18(17):4830-40
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Martin TG 3rd, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Shah JJ, Thomas SK, Weber DM, et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH (Annual Meeting Abstracts) 2012;120:4081
   Google Scholar
• Shah JJ, Stadmauer EA, Abonour R, et al. A multi-center I/II Trial of Carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH (Annual Meeting Abstracts) 2012;120:74
   Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120(9):1801-9
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Reeder CB, Libby EN, et al. results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. ASH (Annual Meeting Abstracts) 2012;120-445
   Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120(14):2817-25
   PubMed Web of Science ®Google Scholar
• Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012;119(24):5661-70
   PubMed Web of Science ®Google Scholar
• Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158(6):739-48
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Asselbergs E, Zweegman S, et al. Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with Multiple Myeloma (MM) who are transplant candidate. ASH (Annual Meeting Abstracts) 2012;120:333
   Google Scholar
• Palumbo A, Bringhen S, Villani O, et al. Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for newly diagnosed Multiple Myeloma (MM) patients. ASH (Annual Meeting Abstracts) 2012;120:730
   Google Scholar
• Singhal S, Siegel D, Martin T, et al. Integrated safety data from phase 2 studies of Monotherapy carfilzomib in patients with relapsed and refractory Multiple Myeloma (MM): an updated analysis. ASH (Annual Meeting Abstract) 2011;118:18769
   Google Scholar